Thrombotic microangiopathy after stem cell transplant in adults
Part of Blood & lymphatic clinical trials.
This study looks at people who have a blood clotting problem called TMA after a stem cell transplant from a donor. It gathers information from routine checkups to learn more about this condition.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have received a donor stem cell transplant (allogeneic HSCT)
- You have had at least 3 signs of TMA (like broken red blood cells, high LDH, low platelets, anemia, high blood pressure, or protein in urine) in two checks within 2 weeks
- You are not in another study that tests a treatment for TMA
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new oral medicine called iptacopan for people who have a serious blood vessel complication after a stem cell transplant (TA-TMA) that is not improving with usual treatments. The goal is to see if iptacopan can help stop the damage and improve recovery.
This trial studies patients who have had a stem cell or solid organ transplant and may have a condition called TMA (small blood clots in vessels) or a viral infection. It aims to understand how certain immune system parts (complement and interferon) affect these conditions.
This trial looks for proteins in the blood that could help detect transplant-related blood vessel damage (called TMA) earlier, so doctors can treat it faster. It involves patients who have had a stem cell transplant from a donor.
This study looks at how often a serious blood clotting problem (TA-TMA) happens after stem cell transplants. It follows two groups: people at high risk for TA-TMA and those with severe GVHD, and may test a drug called eculizumab for those who get TA-TMA.
This trial tests whether eculizumab can safely help people with a serious blood vessel complication called TA-TMA after a stem cell transplant. You may be eligible if you have high-risk features and haven't improved with initial care.
This study looks at signs of a clotting problem in tiny blood vessels (called TMA) that can affect kidney function. The goal is to better understand the role of the body’s complement system and how it relates to different causes of this illness.
Hear when a new Thrombotic Microangiopathy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.